Clinical Trial Update: Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating pegylated interferon alfa-2b in combination with nilotinib to augment complete molecular response in chronic myeloid leukemi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Nilotinib (Tasigna) (nilotinib)
• Pegylated Interferon Alfa-2b (pegylated interferon alfa-2b)

Snippet

Sponsor: Australasian Leukaemia and Lymphoma Group | Conditions: Chronic Myeloid Leukaemia | Phase 2 | Status: COMPLETED